Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer

Jan Adams succeeds Janneke van der Kamp, who will leave Grünenthal to pursue an opportunity outside the company. Jan AdamssucceedsJanneke van der Kamp, who will leave Grünenthal to pursue an opportunity outside the company. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients...

Germany, 30/09/2024 (informazione.it - comunicati stampa - salute e benessere)

Jan Adams succeeds Janneke van der Kamp , who will leave Grünenthal to pursue an opportunity outside the company.

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany , and has affiliates in 27 countries across Europe , Latin America , and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.

More information: https://www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Instagram: grunenthal

Florian Dieckmann , Head of Global Corporate Affairs & Communication
+49 241 569-2555
florian.dieckmann@grunenthal.com

View original content: https://www.prnewswire.co.uk/news-releases/grunenthal-appoints-dr-jan-adams-as-chief-commercial-officer-302262575.html